Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

About the trial

Sponsor

Northwestern University (with National Cancer Institute (NCI))

Tested

Biospecimen Collection (procedure), Computed Tomography (procedure), Echocardiography (procedure), Pembrolizumab (biological), Positron Emission Tomography (procedure), Tazemetostat (drug)

Dates

Started 2024-09-30; completion 2028-11-24

Results posted

Not yet

This phase II trial tests how well pembrolizumab and tazemetostat work to treat patients who have received autologous stem cell transplantation (ASCT) or chimeric antigen receptor (CAR) T cell therapy for aggressive non hodgkins lymphoma. A monoclonal antibody, such as pembrolizumab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Tazemetostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and tazemetostat may work better to treat patients who have received ASCT or CAR-T cell therapy for aggressive non hodgkins lymphoma.

From ClinicalTrials.gov, last updated 2026-09-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ipsen Biopharmaceuticals, Inc reported $1.1M in research payments for this study in 2025 (4 payments).

Products named: Tazverik

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.